UBS Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-8,284
| Closed | -$18.3K | – | 10242 |
|
|
2023
Q2 | $18.3K | Sell |
8,284
-1,992
| -19% | -$4.13K | ﹤0.01% | 6915 |
|
|
2023
Q1 | $26.1K | Buy |
10,276
+10,140
| +7,456% | +$20K | ﹤0.01% | 6888 |
|
|
2022
Q4 | $254 | Sell |
136
-1,044
| -88% | -$2.6K | ﹤0.01% | 10278 |
|
|
2022
Q3 | $3K | Sell |
1,180
-2,116
| -64% | -$5.26K | ﹤0.01% | 9641 |
|
|
2022
Q2 | $6K | Buy |
3,296
+839
| +34% | +$1.83K | ﹤0.01% | 8775 |
|
|
2022
Q1 | $7K | Sell |
2,457
-13,823
| -85% | -$52K | ﹤0.01% | 8889 |
|
|
2021
Q4 | $74K | Buy |
16,280
+13,679
| +526% | +$64.9K | ﹤0.01% | 6566 |
|
|
2021
Q3 | $12K | Buy |
2,601
+616
| +31% | +$3.4K | ﹤0.01% | 7816 |
|
|
2021
Q2 | $13K | Sell |
1,985
-2,544
| -56% | -$20.6K | ﹤0.01% | 7825 |
|
|
2021
Q1 | $32K | Sell |
4,529
-3,009
| -40% | -$21.7K | ﹤0.01% | 6968 |
|
|
2020
Q4 | $47K | Buy |
7,538
+6,069
| +413% | +$35.7K | ﹤0.01% | 6247 |
|
|
2020
Q3 | $8K | Sell |
1,469
-11,658
| -89% | -$57.7K | ﹤0.01% | 7058 |
|
|
2020
Q2 | $69K | Sell |
13,127
-6,127
| -32% | -$27.2K | ﹤0.01% | 5606 |
|
|
2020
Q1 | $61K | Sell |
19,254
-21,537
| -53% | -$79.5K | ﹤0.01% | 5670 |
|
|
2019
Q4 | $164K | Buy |
40,791
+21,088
| +107% | +$73.2K | ﹤0.01% | 5729 |
|
|
2019
Q3 | $85K | Buy |
+19,703
| New | +$78.8K | ﹤0.01% | 5859 |
|
|
2019
Q2 | – | Sell |
-1,500
| Closed | -$8K | – | 8253 |
|
|
2019
Q1 | $8K | Sell |
1,500
-1,537
| -51% | -$9.92K | ﹤0.01% | 6963 |
|
|
2018
Q4 | $16K | Buy |
+3,037
| New | +$23.1K | ﹤0.01% | 6960 |
|
|
2018
Q3 | – | Sell |
-3,500
| Closed | -$36K | – | 8362 |
|
|
2018
Q2 | $36K | Buy |
3,500
+1,560
| +80% | +$17.7K | ﹤0.01% | 6264 |
|
|
2018
Q1 | $25K | Sell |
1,940
-1,145
| -37% | -$17K | ﹤0.01% | 6260 |
|
|
2017
Q4 | $56K | Sell |
3,085
-1,586
| -34% | -$33.1K | ﹤0.01% | 5756 |
|
|
2017
Q3 | $117K | Sell |
4,671
-56,855
| -92% | -$1.32M | ﹤0.01% | 5224 |
|
|
2017
Q2 | $1.48M | Buy |
+61,526
| New | +$1.36M | ﹤0.01% | 3278 |
|
|
2016
Q4 | – | Sell |
-166
| Closed | -$2K | – | 8127 |
|
|
2016
Q3 | $2K | Hold |
166
| – | – | ﹤0.01% | 7436 |
|
|
2016
Q2 | $2K | Hold |
166
| – | – | ﹤0.01% | 7460 |
|
|
2016
Q1 | $3K | Hold |
166
| – | – | ﹤0.01% | 7222 |
|
|
2015
Q4 | $3K | Sell |
166
-840
| -83% | -$16K | ﹤0.01% | 7912 |
|
|
2015
Q3 | $19K | Sell |
1,006
-860
| -46% | -$21.4K | ﹤0.01% | 6759 |
|
|
2015
Q2 | $48K | Buy |
1,866
+1,015
| +119% | +$28.8K | ﹤0.01% | 6046 |
|
|
2015
Q1 | $27K | Sell |
851
-616
| -42% | -$17.7K | ﹤0.01% | 6675 |
|
|
2014
Q4 | $56K | Buy |
+1,467
| New | +$35K | ﹤0.01% | 6359 |
|
UBS Group's PRTK Position: Q3 2023 in Review
UBS Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 8,284 shares — an estimated $18.3K sold.
UBS Group first reported a position in PRTK in Q4 2014 and held it in 31 quarters. The position peaked at $1.48M in Q2 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- UBS Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 8,284 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $18.3K.
- UBS Group first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 31 quarters.
- UBS Group's Paratek Pharmaceuticals, Inc. position peaked at $1.48M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.